1. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.
- Author
-
Mease, Philip J, Gladman, Dafna D, Merola, Joseph F, Nash, Peter, Grieve, Stacy, Laliman-Khara, Victor, Willems, Damon, Taieb, Vanessa, Prickett, Adam R, and Coates, Laura C
- Subjects
- *
THERAPEUTIC use of immunoglobulins , *THERAPEUTIC use of monoclonal antibodies , *MEDICAL information storage & retrieval systems , *ANTI-inflammatory agents , *PATIENT safety , *PSORIATIC arthritis , *LEFLUNOMIDE , *METHOTREXATE , *ANTIRHEUMATIC agents , *META-analysis , *DESCRIPTIVE statistics , *SYSTEMATIC reviews , *ODDS ratio , *MEDLINE , *JANUS kinases , *PHOSPHODIESTERASE inhibitors , *DRUG efficacy , *MEDICAL databases , *SULFONAMIDES , *NEUROTRANSMITTER uptake inhibitors , *INTERLEUKINS , *CHEMICAL inhibitors - Abstract
Objectives To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of IL-17F in addition to IL-17A, vs other biologic and targeted synthetic DMARDs (b/tsDMARDs) for PsA using network meta-analysis (NMA). Methods A systematic literature review (most recent update conducted on 1 January 2023) identified randomized controlled trials (RCTs) of b/tsDMARDs in PsA. Bayesian NMAs were conducted for efficacy outcomes at Weeks 12–24 for b/tsDMARD-naïve and TNF inhibitor (TNFi)-experienced patients. Safety at Weeks 12–24 was analysed in a mixed population. Odds ratios (ORs) and differences of mean change with the associated 95% credible interval (CrI) were calculated for the best-fitting models, and the surface under the cumulative ranking curve (SUCRA) values were calculated to determine relative rank. Results The NMA included 41 RCTs for 22 b/tsDMARDs. For minimal disease activity (MDA), bimekizumab ranked 1st in b/tsDMARD-naïve patients and 2nd in TNFi-experienced patients. In b/tsDMARD-naïve patients, bimekizumab ranked 6th, 5th and 3rd for ACR response ACR20/50/70, respectively. In TNFi-experienced patients, bimekizumab ranked 1st, 2nd and 1st for ACR20/50/70, respectively. For Psoriasis Area and Severity Index 90/100, bimekizumab ranked 2nd and 1st in b/tsDMARD-naïve patients, respectively, and 1st and 2nd in TNFi-experienced patients, respectively. Bimekizumab was comparable to b/tsDMARDs for serious adverse events. Conclusion Bimekizumab ranked favourably among b/tsDMARDs for efficacy on joint, skin and MDA outcomes, and showed comparable safety, suggesting it may be a beneficial treatment option for patients with PsA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF